All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention Brookings Institution, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Neal Dunn
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention Brookings Institution, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.3 for the same window. At 8, the average consequence score sits above the same-window beat average of 6.5. Neal Dunn appears in 1 tracked Legal story from March 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 45 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Neal Dunn. Shared-story counts are live from our verified record — not editorial picks.
The House Select Committee on China has raised alarms over the United States' increasing reliance on Chinese-made active pharmaceutical ingredients and biotech innovation. Lawmakers argue that Beijing is applying a proven industrial playbook to dominate the global medicine supply chain, posing significant national security and regulatory challenges.